CTA
ECYT

Chesley Taft & Associates’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Chesley Taft & Associates’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-29,575
Closed -$135K – 259
2015
Q3 		$135K Sell
29,575
-12,500
-30% -$65.4K 0.01% 220
2015
Q2 		$218K Buy
42,075
+10,775
+34% +$64.6K 0.02% 218
2015
Q1 		$196K Sell
31,300
-1,200
-4% -$6.93K 0.02% 232
2014
Q4 		$204K Sell
32,500
-750
-2% -$4.57K 0.02% 235
2014
Q3 		$202K Buy
33,250
+10,400
+46% +$71K 0.02% 238
2014
Q2 		$151K Sell
22,850
-223,700
-91% -$2.52M 0.02% 245
2014
Q1 		$5.87M Buy
246,550
+22,000
+10% +$319K 0.63% 58
2013
Q4 		$2.4M Buy
224,550
+99,700
+80% +$1.1M 0.24% 108
2013
Q3 		$1.66M Buy
124,850
+22,850
+22% +$361K 0.18% 122
2013
Q2 		$1.34M Buy
+102,000
New +$1.38M 0.16% 133

Other funds holding ECYT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Chesley Taft & Associates's ECYT Position: Q4 2015 in Review

Chesley Taft & Associates sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2015, closing a stake of 29,575 shares — an estimated $135K sold.

Chesley Taft & Associates first reported a position in ECYT in Q2 2013 and held it in 10 quarters. The position peaked at $5.87M in Q1 2014. 102 funds tracked by Wall St. Rank hold ECYT as of Q4 2015.

  • Chesley Taft & Associates reported no remaining Endocyte, Inc. Common Stock position as of Q4 2015 after selling out during the quarter.
  • Chesley Taft & Associates sold 29,575 Endocyte, Inc. Common Stock shares in Q4 2015, an estimated $135K.
  • Chesley Taft & Associates first reported a position in Endocyte, Inc. Common Stock in Q2 2013 and held it in 10 quarters.
  • Chesley Taft & Associates's Endocyte, Inc. Common Stock position peaked at $5.87M in Q1 2014.
  • 102 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2015.

Based on Chesley Taft & Associates's 13F filing for Q4 2015, filed 9 Feb 2016.